arrow
A

Alexander Kutikov

Fox Chase Cancer Center
H指数:59
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

RADIOGRAPHIC RESPONSE TO NEOADJUVANT THERAPY FOR RENAL CELL CARCINOMA DOES NOT CORRELATE TO PATHOLOGIC RESPONSE USING IMMUNE-RELATED RESIDUAL VIABLE TUMOR (IRRVT)

肾细胞癌对新辅助治疗的放射学反应与使用免疫相关残余存活肿瘤(IRRVT)的病理反应不相关

2026-05-010
PRE
ASSESSMENT OF DISEASE RECURRENCE IN COMPLETE RESPONDERS AFTER STOPPING SEQUENTIAL GEMCITABINE AND DOCETAXEL IN PATIENTS WITH HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER

评估高风险非肌层浸润性膀胱癌患者序贯吉西他滨和多西他赛停药后完全应答者的疾病复发情况

2026-05-010
PRE
MARKERS OF SYSTEMIC IMMUNE ACTIVATION DO NOT PREDICT TUMOR RESPONSE BASED ON IMMUNE RELATED RESIDUAL VIABLE TUMOR (%IRRVT)

系统性免疫激活标志物不能基于免疫相关残留存活肿瘤(%IRRVT)预测肿瘤反应

2026-05-010
PRE
MAINTAINING QUALITY OF LIFE DURING SURVIVORSHIP FOR PATIENTS DIAGNOSED WITH MUSCLE INVASIVE BLADDER CANCER: THE USE OF THE ELECTRONIC CANCER RESOURCE, INFORMATION, AND SUPPORT (CRIS) PLATFORM

肌肉浸润性膀胱癌患者生存期生活质量维护:电子癌症资源、信息和支持(CRIS)平台的应用

2026-05-010
PRE
RENAL FUNCTION PRESERVATION WITH NEOADJUVANT THERAPY IN RENAL CELL CARCINOMA PATIENTS WITH CHRONIC KIDNEY DISEASE

慢性肾脏病肾细胞癌患者中通过新辅助治疗保护肾功能

2026-05-010
PRE
Neoadjuvant and Adjuvant Immune-based Approach for Renal Cell Carcinoma: Pros, Cons, and Future Directions

肾细胞癌的新辅助和辅助免疫疗法:优势、劣势及未来方向

2024-09-010
OAAI
A Randomized, Controlled Trial Evaluating Perioperative Risk-stratification and Risk-based, Protocol-driven Management After Elective Major Cancer Surgery

一项评估择期大癌症手术后围手术期风险分层和基于风险的协议驱动管理的随机对照试验

2024-07-240
PRE
Re: Giuseppe Basile, Giuseppe Fallara, Paolo Verri, et al. The Role of 99mTc-Sestamibi Single-photon Emission Computed Tomography/Computed Tomography in the Diagnostic Pathway for Renal Masses: A Systematic Review and Meta-analysis.

回复: Giuseppe Basile,Giuseppe Fallara,Paolo Verri等。99mTc-Sestamibi单光子发射计算机断层扫描/计算机断层扫描在肾脏肿块诊断途径中的作用: 系统综述和荟萃分析。

2024-02-010
PRE
Transition to Value-based Healthcare: Development, Implementation, and Results of an Optimal Surgical Care Framework at a National Cancer Institute-designated Comprehensive Cancer Center

向基于价值的医疗保健过渡: 国家癌症研究所指定的综合癌症中心的最佳外科护理框架的开发,实施和结果

2024-01-011
PRE
Diabetes, Obesity, and Pathological Upstaging in Renal Cell Carcinoma: Results From a Large Multi-institutional Consortium

肾细胞癌的糖尿病,肥胖和病理升级: 来自大型多机构联盟的结果

2023-11-017
PRE
Preference Elicitation and Treatment Decision-Making Among Men Diagnosed With Prostate Cancer: Randomized Controlled Trial Results of Healium

被诊断患有前列腺癌的男性的偏好引发和治疗决策: Healium的随机对照试验结果

2023-10-201
OAAI
Real-time estimation of nephron activity with a linear measurement system (RENAL-MS) predicts postoperative estimated glomerular filtration rate

使用线性测量系统 (肾脏-MS) 实时估计肾单位活动可预测术后估计的肾小球滤过率

2023-10-021
OAAI
Clinical Performance of Technetium-99m-Sestamibi SPECT/CT Imaging in Differentiating Oncocytic Tumors From Renal Cell Carcinoma in Routine Clinical Practice

Technetium-99m-Sestamibi SPECT/CT显像在鉴别嗜酸细胞肿瘤和肾细胞癌中的临床表现

2023-09-0112
PRE
Partial versus radical nephrectomy for complex renal mass: multicenter comparative analysis of functional outcomes (Rosula collaborative group)

部分肾切除术与根治性肾切除术治疗复杂肾肿块: 功能结局的多中心比较分析 (Rosula协作组)

2023-08-0115
PRE